Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 3OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 51Lung Neoplasms 32Lymphoma 31Breast Neoplasms 29Multiple Myeloma 27Prostatic Neoplasms 25Melanoma 23Carcinoma, Non-Small-Cell Lung 23Leukemia, Myeloid, Acute 22Neoplasm Metastasis 21Ovarian Neoplasms 20Lymphoma, Non-Hodgkin 20Hematologic Neoplasms 20Glioma 18Pancreatic Neoplasms 17Urinary Bladder Neoplasms 16Neuroblastoma 15Colorectal Neoplasms 15Burkitt Lymphoma 15Carcinoma, Renal Cell 14Sarcoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Colonic Neoplasms 13Leukemia, Lymphocytic, Chronic, B-Cell 12Carcinoma 12Brain Neoplasms 12Triple Negative Breast Neoplasms 11Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Oropharyngeal Neoplasms 11

Interventions

pomalidomide 1Vincristine 1Rituximab 1Prednisone 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Plasmablastic Lymphoma × 30 days × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡